HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drugstore.com launches microsite

This article was originally published in The Rose Sheet

Executive Summary

DeluxeSalonSupply.com, aimed at salon and spa owners, is drugstore.com's latest microsite intended to "provide beauty professionals with a faster, more efficient way to order supplies," the Internet retailer announces in a May 10 release. The site features nail, skin, hair and massage products in addition to office and salon furniture, apparel, linens and cleaning supplies. Users will also benefit from online tools to make ordering easier, as well as a customer rewards program, the company notes. Drugstore.com has said that it will launch up to eight focused sales portals in 2010, including one for natural products and another for vitamins (1"The Rose Sheet" Jan. 18, 2010)

You may also be interested in...



Drugstore.com Widens Range Of Niche Offerings Through Microsites

For drugstore.com, the future of electronic retail is narrow consumer niches like those found in the firm's growing microsite lineup

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel